Roles of HNF-1β in kidney development and congenital cystic diseases  by Igarashi, Peter et al.
Kidney International, Vol. 68 (2005), pp. 1944–1947
Roles of HNF-1b in kidney development and congenital
cystic diseases
PETER IGARASHI, XINLI SHAO, BRIAN T. MCNALLY, and THOMAS HIESBERGER
Department of Internal Medicine and Division of Basic Science, University of Texas Southwestern Medical Center, Dallas, Texas
Roles of HNF-1b in kidney development and congenital cystic
diseases. Hepatocyte nuclear factor-1b (HNF-1b) is a Pit-1/Oct-
1/Unc-86 (POU)/homeodomain-containing transcription factor
that regulates tissue-specific gene expression in the kidney, liver,
pancreas, and other epithelial organs. Mutations of HNF-1b
produce maturity-onset diabetes of the young type 5 (MODY5)
and are associated with congenital cystic abnormalities of the
kidney. Transgenic mice expressing mutant HNF-1b under the
control of a kidney-specific promoter develop kidney cysts and
renal failure, which is similar to the phenotype of humans with
MODY5. Similarly, kidney-specific deletion of HNF-1b using
Cre/loxP recombination results in renal cyst formation. HNF-
1b directly regulates the Pkhd1 promoter. HNF-1b mutant mice
show decreased expression of Pkhd1, the gene that is mutated
in humans with autosomal-recessive polycystic kidney disease
(ARPKD). These studies demonstrate that HNF-1b is required
for the development of the mammalian kidney. They establish a
previously unrecognized link between two renal cystic diseases,
MODY5 and ARPKD, and suggest that the mechanism of cyst
formation in humans with mutations of HNF-1b involves down-
regulation of PKHD1 gene transcription.
Hepatocyte nuclear factor-1b (HNF-1b , vHNF1) is a
transcription factor that regulates tissue-specific gene ex-
pression in the kidney, liver, pancreas, and other organs
[1, 2]. HNF-1b and the related family member, HNF-
1a, have a similar structure consisting of an N-terminal
dimerization domain, a Pit-1/Oct-1/Unc-86 (POU) do-
main and homeodomain that mediate DNA binding, and
a C-terminal transcriptional activation domain (Fig. 1).
HNF-1a and HNF-1b recognize the consensus sequence
5′-GTTAATNATTAAC-3′ and bind to DNA as homod-
imers or heterodimers. In general, HNF-1a and HNF-1b
bind to the promoters of target genes and activate tran-
scription, although transcriptional repression has also
been reported. HNF-1a and HNF-1b were first dis-
covered because of their roles in liver-specific gene
regulation, but both proteins are also expressed in other
epithelial organs, including the kidney. HNF-1a is ex-
pressed in renal proximal tubules, whereas HNF-1b is
expressed in tubular epithelial cells in all segments of the
nephron and in renal collecting ducts [3, 4]. Neither tran-
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scription factor is expressed in glomerular tufts, blood
vessels, or interstitial cells. During embryonic develop-
ment, HNF-1b is expressed in the branching ureteric
bud that will give rise to the renal collecting system and
ureter as well as in comma- and S-shaped bodies that will
form the nephrons proper. HNF-1a is restricted to late
S-shaped bodies and developing proximal tubules. HNF-
1b is also expressed in the mesonephric (Wolffian) duct,
which is the anlage of the vas deferens and epididymis in
males, and the Mu¨llerian duct, which is the anlage of the
oviduct, uterus, and cervix in females.
HNF-1a regulates the tissue-specific expression of
genes that encode transport proteins in the renal prox-
imal tubule. Knockout mice that lack HNF-1a have mor-
phologically normal kidneys but develop glucosuria due
to decreased expression of the sodium/glucose cotrans-
porter, Sglt2 [3, 5]. Defects in the renal reabsorption of
glucose are also seen in humans with mutations of HNF-
1a. HNF-1a knockout mice also exhibit phosphaturia,
which has been attributed to decreased expression of
Npt1 and Npt4 in the proximal tubule [6]. In contrast
to HNF-1a, the functions of HNF-1b in the kidney have
been poorly understood. HNF-1b recognizes the same
DNA sequence as HNF-1a and could also be involved
in kidney-specific gene regulation. For example, HNF-1b
binding sites have been identified in the promoters of the
genes encoding kidney-specific Ksp-cadherin (Cdh16)
and Na-K-Cl cotransporter (Nkcc2) [7] [abstract; Whyte
DA, et al, J Am Soc Nephrol 6:713A, 1995]. Studies in
lower vertebrates suggest that HNF-1b plays an impor-
tant role in nephrogenesis. Transgenic expression of mu-
tant HNF-1b in Xenopus embryos leads to abnormal
development of the pronephros [8, 9], and mutation of
zebrafish HNF-1b produces cysts in the pronephric
tubules [10]. However, the roles of HNF-1b in the de-
velopment of the mammalian kidney have not been ap-
parent because HNF-1b knockout mice die prior to renal
organogenesis [11, 12].
Mutations of HNF-1b in humans produce maturity-
onset diabetes of the young, type 5 (MODY5). MODY5
is a rare familial form of type 2 diabetes mellitus that is
characterized by autosomal-dominant inheritance, early
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106 178 231 310 55 Fig. 1. Structure of wild-type and mutant
hepatocyte nuclear factor (HNF-1b). Upper
bar depicts wild-type human HNF-1b . Boxes
indicate the N-terminal dimerization domain,
POU domain, homeodomain, and C-terminal
activation domain. Lower bars depict muta-
tions of HNF-1b in humans with maturity-
onset diabetes of the young, type 5 (MODY5)
selected from ∼30 described in the litera-
ture. Most mutations affect the DNA binding
domain. The P328L329fsdelCCTCT mutation
produces a deletion of the C-terminal do-
main and addition of 29 amino acids from the
shifted reading frame (hatched box).
age of onset, impaired insulin secretion, and absence of
obesity [13]. MODY5 is frequently, perhaps invariably,
associated with congenital abnormalities of the kidney
and genitourinary tract [14, 15]. The most common kid-
ney abnormalities involve the formation of cysts in the
renal tubules, and the acronym RCAD (renal cysts and
diabetes) has been coined to describe this syndrome.
The spectrum of congenital renal cystic abnormalities
includes simple cysts, multicystic renal dysplasia, and hy-
poplastic glomerulocystic kidney disease. Renal involve-
ment is often severe and can lead to kidney failure. In
addition to cysts, other kidney abnormalities that have
been observed in MODY5 include oligomeganephronia,
familial juvenile hyperuricemic nephropathy, and renal
agenesis or hypoplasia [16]. Abnormalities of the male
and female genital tract are also seen in some patients.
To date, more than 30 different mutations of HNF-1b
have been identified in humans with MODY5, some of
which are shown in Figure 1. The molecular mechanism
by which mutation of one allele of HNF-1b produces dis-
ease has been controversial. The A263fsinsGG mutation
affects the DNA-binding domain and has been shown to
produce a dominant-negative mutant [17], whereas the
P328L329fsdelCCTCT mutation deletes the C-terminal
domain and has been reported to produce a gain-of-
function mutant [8]. Although MODY5 is a rare familial
disorder, mutations of HNF-1b may also be responsible
for a subset of the sporadic congenital renal abnormal-
ities that occur frequently in humans. A recent survey
of 105 subjects with sporadic renal hypoplasia/dysplasia
and chronic kidney disease found mutations of HNF-1b
in three individuals [abstract; Salomon R, et al, J Am
Soc Nephrol 15:662A, 2004]. These findings suggest that
mutations of HNF-1b may be a more common cause of
congenital renal abnormalities than is currently appreci-
ated. HNF-1b may also be involved in the pathogenesis
of renal cancer, since biallelic inactivation of the gene
has been identified in chromophobe renal cell carcino-
mas [18].
To create an animal model of the renal abnormalities
in MODY5, we generated transgenic mice expressing a
dominant-negative HNF-1b mutant under the control
of a kidney-specific promoter [19]. A tissue-specific
promoter was required for these experiments, because
constitutive inhibition of HNF-1b produces embryonic
lethality. Transgenic mice expressing dominant-negative
HNF-1b are viable at birth but develop kidney cysts and
renal failure. Cysts are observed in the renal tubules and
collecting ducts as well as in Bowman’s capsules. The
severity of cyst formation is directly correlated with the
level of expression of the mutant transgene. These results
indicate that kidney-specific expression of a dominant-
negative HNF-1b mutant produces congenital cystic kid-
ney disease in mice, similar to the phenotype of humans
with MODY5.
To determine how mutations of HNF-1b produce kid-
ney cysts, we measured the expression of other cys-
tic disease genes in the kidneys from the transgenic
mice. A striking abnormality was a marked reduction
in the expression of the autosomal-recessive polycystic
kidney disease (ARPKD) gene, Pkhd1. Real-time re-
verse transcription-polymerase chain reaction (RT-PCR)
showed that Pkhd1 expression is reduced by up to 70%
in the cystic kidneys compared with nontransgenic con-
trols. In situ hybridization showed that Pkhd1 mRNA
transcripts are absent in the cells lining the cysts but can
be detected in the surrounding noncystic tubules. In con-
trast, the expression of the ADPKD genes (Pkd1 and
Pkd2) is not affected in this model. ARPKD is a con-
genital cystic disorder that is characterized by dilatation
of the collecting ducts, bilateral kidney enlargement, and
intrauterine renal failure [20]. The cystic collecting ducts
are invariably associated with biliary dysgenesis, a ductal
plate malformation that produces aberrant intrahepatic
bile ducts and portal fibrosis. ARPKD is caused by mu-
tations of Pkhd1, which encodes a membrane protein of
unknown function that has been localized to primary cilia
[21]. The expression of Pkhd1 is tissue-specific and over-
laps with the expression of HNF-1b [22]. Pkhd1 is highly
expressed in renal collecting ducts with lower levels of
expression in proximal and distal tubules. In the devel-
oping metanephros, Pkhd1 is expressed in the branching
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ureteric bud and developing tubules. In the developing
liver Pkhd1 is expressed in epithelial cells of the ductal
plate, and expression continues in the intra- and extrahep-
atic bile ducts in the mature liver. Additional sites of over-
lapping expression include the mesonephros, Wolffian
duct, pancreatic ducts, and gastrointestinal tract. Liver-
specific inactivation of HNF-1b produces a ductal plate
malformation that resembles the biliary dysgenesis seen
in humans with ARPKD [23].
The preceding results suggested that HNF-1b might
directly regulate Pkhd1 transcription. To test this hy-
pothesis, we cloned and characterized the mouse Pkhd1
promoter [19]. A genomic fragment containing the first
two exons and 9 kb of 5′ flanking sequence of Pkhd1
was obtained from a BAC clone, and the major tran-
scription initiation site was mapped by primer extension.
The Pkhd1 promoter was linked to a luciferase reporter
gene and transfected into cultured cells. Transfection into
renal epithelial cells produced high levels of luciferase,
whereas no significant activity was produced in fibrob-
lasts, which indicated that the activity of the promoter
was cell-specific. Truncation of the promoter from 6.6 kb
to 1.8 kb does not significantly affect its activity in kidney
cells, whereas further deletions decrease promoter activ-
ity. The proximal Pkhd1 promoter contains a DNase I
hypersensitive site that is present in renal epithelial cells
but not in fibroblasts, which suggests that activation of
the promoter is associated with local alterations in chro-
matin structure. An evolutionarily conserved binding site
for HNF-1 is located 60 bp upstream to the transcription
initiation site near the region of DNase I hypersensitivity.
HNF-1b binds specifically to the −60 bp site and stimu-
lates Pkhd1 promoter activity, whereas mutations of the
HNF-1 site or expression of a dominant-negative HNF-
1b mutant inhibit promoter activity. Collectively, these
findings demonstrate that HNF-1b directly regulates the
Pkhd1 promoter.
To confirm the role of HNF-1b in the pathogenesis
of renal cystic diseases, we collaborated with Dr. Marco
Pontoglio at the Pasteur Institute to conditionally inac-
tivate the HNF-1b gene using kidney-specific Cre/loxP
recombination [24]. Mice expressing Cre recombinase
under the control of the kidney-specific Ksp-cadherin
promoter were crossed with mice carrying a floxed HNF-
1b gene to produce progeny in which HNF-1b was
deleted specifically in the kidney and genitourinary tract.
Kidney-specific inactivation of HNF-1b leads to postna-
tal lethality and renal failure. The mutant mice develop
hydroureter and enlarged kidneys that contain multiple
cysts which are lined by a hyperplastic epithelium. Sim-
ilar to the findings in the dominant-negative HNF-1b
transgenic mice, the expression of Pkhd1 is markedly de-
creased in the cystic kidneys of HNF-1b knockout mice.
In addition, there is a reduction in the expression of
Umod, the gene that is mutated in familial juvenile hype-
ruricemic nephropathy and medullary cystic kidney dis-
ease type 2, and a smaller decrease in the expression of
the ADPKD gene, Pkd2. These results uncovered a tran-
scriptional hierarchy involving HNF-1b and several cys-
tic disease genes. In vivo chromatin immunoprecipitation
experiments showed that HNF-1b binds to several DNA
elements in the 5′ flanking regions of the Umod, Pkhd1,
and Pkd2 genes. In addition to the site at −60 bp, the
Pkhd1 gene contains HNF-1b binding sites at −200 bp,
−35 kb, and within intron 5.
To understand how HNF-1b activates the Pkdh1 pro-
moter, we first examined the role of the C-terminal
domain [25]. Removal of 236 amino acids from the C-
terminus of HNF-1b does not interfere with dimerization
or DNA-binding but produces a dominant-negative in-
hibitor of a chromosomally integrated Pkhd1 promoter.
The C-terminal domain of HNF-1b contains a transcrip-
tional activation domain that remains functional when
fused to a heterologous DNA-binding domain. Deletion
analysis showed that the activation domain extends from
amino acids 352-483. The activation of the Pkhd1 pro-
moter by wild-type HNF-1b is stimulated by CBP [cyclic
adenosine monophosphate (cAMP)-responsive element
binding protein (CREB) binding protein] and P/CAF
(p300/CBP-associated factor), which are transcriptional
coactivators that have intrinsic histone acetyl transferase
activity. Sodium butyrate, an inhibitor of histone deacety-
lase (HDAC), also stimulates promoter activity, whereas
an inhibitor of DNA methylation has no effect. CBP and
P/CAF directly interact with the C-terminal domain of
HNF-1b , and deletion of the C-terminal domain prevents
the coactivators from activating the Pkhd1 promoter.
These results indicate that HNF-1b activates Pkhd1 tran-
scription by recruiting coactivators that promote histone
acetylation and chromatin remodeling at the promoter.
Deletion mutants lacking the C-terminal domain function
as dominant-negative mutants, possibly by preventing the
recruitment of coactivators.
To test whether the C-terminal domain is required
for the function of HNF-1b in vivo, we expressed the
C-terminal deletion mutant in transgenic mice using
a kidney-specific promoter [25]. Expression of the C-
terminal deletion mutant produces renal cysts, increased
cell proliferation, and dilatation of the ureter, which is
similar to the phenotype of mice with kidney-specific in-
activation of HNF-1b . The expression of Pkhd1 is inhib-
ited in cystic collecting ducts but not in noncystic proximal
tubules, despite expression of the HNF-1b deletion mu-
tant in both nephron segments. These results verify that
deletion of the C-terminal domain of HNF-1b , as re-
sults from some disease-causing MODY5 mutations, pro-
duces a dominant-negative mutation. Cyst formation in
the deletion mutants correlates with inhibition of Pkhd1
expression rather than transgene expression per se, which
further argues that mutations of HNF-1b produce kidney
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cysts by down-regulating Pkhd1. The expression of HNF-
1a in proximal tubules may protect against cystogenesis
in this nephron segment.
In summary, our studies confirm that HNF-1b plays a
central role in the development of the mammalian kidney.
The identification of Pkhd1 as an HNF-1b gene target
establishes a previously unrecognized link between two
congenital renal cystic diseases, MODY5 and ARPKD,
and suggests that cyst formation in humans with muta-
tions of HNF-1b results from inhibition of PKHD1 gene
transcription. Further studies of the transcriptional hi-
erarchy involving HNF-1b and cystic disease genes may
clarify the molecular mechanisms of renal epithelial dif-
ferentiation and the pathogenesis of congenital renal cys-
tic diseases.
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